Stock Yards Bank & Trust Co. Sells 13,435 Shares of Zoetis Inc. $ZTS

Stock Yards Bank & Trust Co. trimmed its position in Zoetis Inc. (NYSE:ZTS) by 14.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 77,222 shares of the company’s stock after selling 13,435 shares during the quarter. Stock Yards Bank & Trust Co.’s holdings in Zoetis were worth $9,716,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of ZTS. Halbert Hargrove Global Advisors LLC raised its holdings in shares of Zoetis by 496.6% in the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after purchasing an additional 144 shares during the period. Global Wealth Strategies & Associates bought a new stake in shares of Zoetis in the 4th quarter valued at about $25,000. Lodestone Wealth Management LLC bought a new stake in shares of Zoetis in the 4th quarter valued at about $30,000. KERR FINANCIAL PLANNING Corp bought a new stake in shares of Zoetis in the 3rd quarter valued at about $31,000. Finally, Holos Integrated Wealth LLC bought a new stake in shares of Zoetis in the 4th quarter valued at about $32,000. 92.80% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Morgan Stanley set a $160.00 price target on shares of Zoetis in a research note on Thursday, December 18th. Bank of America upped their price target on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Friday, February 13th. William Blair reiterated an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Weiss Ratings lowered shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 27th. Finally, HSBC set a $140.00 price target on shares of Zoetis in a research note on Wednesday, December 10th. Six equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $152.91.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $118.17 on Tuesday. The company’s 50 day moving average price is $122.60 and its two-hundred day moving average price is $127.75. Zoetis Inc. has a 12-month low of $113.29 and a 12-month high of $172.23. The firm has a market cap of $49.88 billion, a PE ratio of 19.63, a PEG ratio of 1.80 and a beta of 0.98. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The firm had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. During the same quarter in the prior year, the business posted $1.40 EPS. The business’s revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio is presently 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.